TransDigm Enters Agreement for Arkwin Industries Acquisition

TransDigm Group Incorporated announced today that it has entered into a definitive agreement to acquire Arkwin Industries, Inc. (Arkwin or the Company), for approximately $286 million in cash. The acquisition, subject to regulatory approvals and other customary closing conditions, is expected to close in the third quarter of fiscal 2013.

Arkwin, located on Long Island, New York, manufactures proprietary, highly engineered aerospace hydraulic and fuel system components for commercial and military aircraft, helicopters and other specialty applications. The major commercial end-use platforms include the Boeing 737 and 777, Airbus 320, and Bombardier and Embraer regional jets. The major military end-use platforms include the Lockheed JSF, C-130 and F-16; Sikorsky SH-60, S-76 and S-92; Boeing CH-47 and F/A-18. Additionally, the Company has product positions on various ground-based aero derivative turbine engines. Arkwin had calendar year 2012 revenues of approximately $95 million. Aftermarket accounts for approximately 40% of the revenues and the commercial market about 50% of the revenues.

W. Nicholas Howley , Chairman and CEO of TransDigm Group Incorporated, stated, "Arkwin is a long standing manufacturer of proprietary products with established positions on high use platforms, strong aftermarket content and an outstanding reputation. The highly engineered products will allow us to expand our content on a number of substantial platforms and engine applications. Arkwin fits well with our consistent product and acquisition strategy. As with all TransDigm acquisitions, we see opportunities for significant value creation."

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.